Theranostics 2023; 13(9):2787-2799. doi:10.7150/thno.81993 This issue Cite

Research Paper

Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis

Qianru Mei1#, Zhenhua Yang1#, Zhengkai Xiang2#, He Zuo1, Zijing Zhou3, Xiaochuan Dong4, Ludan Zhang1, Wenhui Song1, Yi Wang1, Qinghua Hu1, Yong Zhou5, Jing Qu1✉

1. School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
2. Department of Thoracic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China.
3. Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
4. Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
5. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, the University of Alabama at Birmingham, Birmingham, AL, United States.
# Equal contribution

Citation:
Mei Q, Yang Z, Xiang Z, Zuo H, Zhou Z, Dong X, Zhang L, Song W, Wang Y, Hu Q, Zhou Y, Qu J. Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis. Theranostics 2023; 13(9):2787-2799. doi:10.7150/thno.81993. https://www.thno.org/v13p2787.htm
Other styles

File import instruction

Abstract

Graphic abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of unknown etiology with no cure. A better understanding of the disease processes and identification of druggable targets will benefit the development of effective therapies for IPF. We previously reported that MDM4 promoted lung fibrosis through the MDM4-p53-dependent pathway. However, it remained unclear whether targeting this pathway would have any therapeutic potential. In this study, we evaluated the efficacy of XI-011, a small molecular inhibitor of MDM4, for treating lung fibrosis. We found that XI-011 significantly reduced MDM4 expression and increased the expression of total and acetylated p53 in primary human myofibroblasts and a murine fibrotic model. XI-011 treatment resulted in the resolution of lung fibrosis in mice with no notable impact on normal fibroblast death or the morphology of healthy lungs. Based on these findings, we propose that XI-011 might be a promising therapeutic drug candidate for treating pulmonary fibrosis.

Keywords: Idiopathic pulmonary fibrosis, MDM4-p53 pathway, MDM4 inhibitor, XI-011, Therapeutic drug.


Citation styles

APA
Mei, Q., Yang, Z., Xiang, Z., Zuo, H., Zhou, Z., Dong, X., Zhang, L., Song, W., Wang, Y., Hu, Q., Zhou, Y., Qu, J. (2023). Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis. Theranostics, 13(9), 2787-2799. https://doi.org/10.7150/thno.81993.

ACS
Mei, Q.; Yang, Z.; Xiang, Z.; Zuo, H.; Zhou, Z.; Dong, X.; Zhang, L.; Song, W.; Wang, Y.; Hu, Q.; Zhou, Y.; Qu, J. Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis. Theranostics 2023, 13 (9), 2787-2799. DOI: 10.7150/thno.81993.

NLM
Mei Q, Yang Z, Xiang Z, Zuo H, Zhou Z, Dong X, Zhang L, Song W, Wang Y, Hu Q, Zhou Y, Qu J. Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis. Theranostics 2023; 13(9):2787-2799. doi:10.7150/thno.81993. https://www.thno.org/v13p2787.htm

CSE
Mei Q, Yang Z, Xiang Z, Zuo H, Zhou Z, Dong X, Zhang L, Song W, Wang Y, Hu Q, Zhou Y, Qu J. 2023. Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis. Theranostics. 13(9):2787-2799.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image